Trials / Active Not Recruiting
Active Not RecruitingNCT06157216
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
Circulating Tumor DNA Minimal Residual Disease-guided Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, single-arm, interventional study to explore the feasibility of circulating tumor DNA (ctDNA)-MRD testing to guide postoperative adjuvant treatment strategies in patients with stage II-III gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRD-guided therapy | MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive. |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2027-04-01
- Completion
- 2029-04-01
- First posted
- 2023-12-05
- Last updated
- 2025-01-07
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06157216. Inclusion in this directory is not an endorsement.